GlassScriptPhysician profile
Gillian Graham Smith
NPI 1639566680
$2,055.14
in general payments reported to CMS, 2019-2025
27 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $147 · 2021: $319 · 2022: $333 · 2023: $467 · 2024: $492 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $527.33 | 2020-2025 | |
| Therapeuticsmd, INC. | $137.93 | 2019 | |
| Pfizer INC. | $130.06 | 2022-2024 | |
| Daiichi Sankyo INC. | $97.58 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $94.91 | 2022-2025 | |
| Biogen, INC. | $89.52 | 2024-2025 | Zurzuvae |
| Medtronic USA, INC. | $89.31 | 2020 | |
| Intuitive Surgical, INC. | $87.80 | 2023 | Da Vinci Surgical System |
| Exeltis, USA INC. | $80.35 | 2023-2025 | Slynd |
| Organon LLC | $80.13 | 2022-2024 | Nexplanon |
| Myriad Women'S Health, INC. | $79.33 | 2023 | Myrisk |
| Astellas Pharma US INC | $74.19 | 2023-2024 | Veozah, Myrbetriq |
| Stryker Corporation | $65.29 | 2024 | Photonsaber Y |
| Sumitomo Pharma America, INC. | $60.61 | 2023-2024 | Gemtesa, Myfembree |
| Hologic Sales and Service, LLC | $49.67 | 2021-2025 | Aptima |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $43.63 | 2022 | |
| Millicent US INC | $43.51 | 2024-2025 | Intrarosa, Femring |
| Bayer Healthcare Pharmaceuticals INC. | $41.84 | 2022-2023 | |
| Novo Nordisk INC | $32.70 | 2023 | Wegovy |
| Mylan Pharmaceuticals INC. | $29.88 | 2021 | |
| Endomagnetics LTD | $22.57 | 2022 | |
| Davol INC. | $18.91 | 2025 | Arista |
| Scynexis, INC. | $18.77 | 2022 | |
| Pharmacosmos Therapeutics INC. | $17.34 | 2024 | Monoferric |
| Shield Therapeutics INC | $14.79 | 2024 | |
| Agile Therapeutics, INC. | $14.21 | 2021 | |
| Avion Pharmaceuticals | $12.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gillian Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.